The transcranial pulse stimulation (TPS®) as a method in the treatment of the central nervous system of patients with Alzheimer`s dementia

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00033282

Enrollment

100

Registered

2024-01-24

Start date

2023-12-01

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F00

Interventions

Group 1: Patients with dementia in Alzheimers disease who are treated with the transcranial pulse stimulation (TPS) in an outpatient setting of a psychiatric-psychosomatic clinic (Wahrendorff Klinikum

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Main Diagnosis: Alzheimer's Disease

Exclusion criteria

Exclusion criteria: Other Main Diagnosis than Alzheimer's Disease

Design outcomes

Primary

Measure	Time frame
Development of cognitive performance (assessed by MOCA) and depressive symptom burden (assessed by GDS) during TPS treatment, follow-up design. The data from patients with AD are collected at the beginning of treatment (t1) and then every three months during the course of treatment until a point in time of at least four follow-up measurements (t2 = after 3 months, t3 = after 6 months, t4 = after 9 months, t5 = after 12 months).	—

Measure

Time frame

Development of cognitive performance (assessed by MOCA) and depressive symptom burden (assessed by GDS) during TPS treatment, follow-up design. The data from patients with AD are collected at the beginning of treatment (t1) and then every three months during the course of treatment until a point in time of at least four follow-up measurements (t2 = after 3 months, t3 = after 6 months, t4 = after 9 months, t5 = after 12 months).

—

Secondary

Measure	Time frame
Patients' personal experience/assessment of TPS-treatment (assessed by questionnaire), follow-up design. The data from patients with AD are collected at the beginning of treatment (t1) and then every three months during the course of treatment until a point in time of at least four follow-up measurements (t2 = after 3 months, t3 = after 6 months, t4 = after 9 months, t5 = after 12 months).	—

Countries

Germany

Contacts

Public ContactMarc Ziegenbein

Wahrendorff Klinikum

marc.ziegenbein@wahrendorff.de+49 (5132) 901851

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 14, 2026